文献速递糖尿病

GRADE随机试验中四种降糖药持续葡萄糖监测特征的比较

Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

GRADE研究纳入1080例二甲双胍治疗的2型糖尿病患者,在中位随访约5年时进行2周盲法CGM分析,比较加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀后的CGM指标及共识目标达成情况。西格列汀和利拉鲁肽组TIR70-180最高、TBR<70和%CV最低;格列美脲组TIR最低且低血糖事件最多。

要点

  • 西格列汀与利拉鲁肽的TIR最高、TBR和血糖变异最低
  • 格列美脲TIR最低、低血糖事件最多且是唯一出现日间低血糖的药物
  • 按HbA1c分层后平均血糖无差异,但甘精胰岛素和格列美脲的%CV与TBR更高

核心结论

  • 肠促胰岛素类药物(利拉鲁肽、西格列汀)血糖变异最低、低血糖最少且CGM目标达成最佳。
  • CGM指标与图谱可提供超越HbA1c的临床信息以指导糖尿病管理。

研究设计与样本

  • GRADE随机试验中,1080例接受二甲双胍治疗的2型糖尿病患者在中位随访约5年时进行2周盲法CGM分析。
  • 患者随机加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀之一,随访5±1.3年。

主要发现

  • 西格列汀和利拉鲁肽组TIR70-180最高,TBR<70和%CV最低。
  • 格列美脲组TIR70-180最低,%CV、TBR<70及CGM低血糖事件数最高(P<0.001),且是唯一出现日间低血糖的药物。
  • 西格列汀和利拉鲁肽在达成TBR<54<1%及TIR70-180>70%且TBR<70<4%的共识目标上最佳(P<0.001)。
  • 按HbA1c分层后各组平均血糖无差异,但甘精胰岛素和格列美脲在各HbA1c层的%CV和TBR<70更高。

关键数值与推荐

  • 共识目标包括TBR<54<1%以及TIR70-180>70%且TBR<70<4%。
  • 格列美脲组CGM低血糖事件数最高,P<0.001。

临床怎么用

  • 选择降糖药物时可参考CGM指标评估血糖变异和低血糖风险,而不仅依赖HbA1c。
  • 对低血糖风险较高者,肠促胰岛素类药物在CGM目标达成上可能更优。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glycemic management metrics derived from continuous glucose monitoring (CGM) are increasingly recognized as important therapeutic targets. We performed one of the first comparisons of CGM metrics and achievement of CGM targets among four classes of glucose-lowering medications in combination with metformin. RESEARCH DESIGN AND METHODS: The Glycemia Reduction Approaches in Diabetes (GRADE) study randomly assigned participants with type 2 diabetes and taking metformin to add one of four glucose-lowering medications (insulin glargine, glimepiride, liraglutide, or sitagliptin) and followed them for glycemic outcomes for 5 ± 1.3 years. A 2-week masked CGM analysis was conducted midstudy in 1,080 participants to evaluate CGM metrics, 24-h ambulatory glucose profile, and achievement of consensus goals. Treatment effects among the four groups were compared. RESULTS: The sitagliptin and liraglutide groups had the highest time in range 70-180 mg/dL (TIR70-180) and the lowest time below range <70 mg/dL (TBR<70) and percentage coefficient of variation (%CV). The glimepiride group had the lowest TIR70-180, and the highest %CV, TBR<70, and number of CGM-derived hypoglycemic events (P < 0.001), and was the only drug showing daytime hypoglycemia. Sitagliptin and liraglutide were best for achieving consensus goals of very low TBR<54 <1% and the combined metric of TIR70-180 >70% and TBR<70 <4% (P < 0.001). When stratified by HbA1c, mean glucose did not differ among treatments, but %CV and TBR<70 were higher with glargine and glimepiride within each HbA1c stratum. CONCLUSIONS: Incretin class drugs had the lowest %CV, the least hypoglycemia, and best achievement of CGM-based glycemic targets. CGM metrics and profiles provide clinical insights, beyond HbA1c, to guide diabetes management.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bergenstal RM, Crandall JP, Rosin SP, et al. Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial. Diabetes Care. 2026. PMID: 41925680. doi:10.2337/dc25-3055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。